Recently, the LAG3 antibody relatlimab has been approved by the FDA for the treatment of resistant melanoma, evidencing the safety of the therapy [71] and offering hope for the treatment of resistant breast cancers. The gene discussed is LAG3; the disease is breast carcinoma.